GW Pharmaceuticals PLC | Ownership
Companies that own GW Pharmaceuticals PLC
OrbiMed Advisors LLC
1,259,838
0.37%
-86,467
0.16%
09/30/2017
APG Asset Management NV
776,747
0.23%
-299,202
0.01%
03/31/2018
Stifel, Nicolaus & Co., Inc.
166,689
0.05%
5,051
5.17%
08/02/2018
National Financial Services LLC (Broker)
130,311
0.04%
3,949
0.16%
08/02/2018
Raymond James & Associates, Inc. (Invt Mgmt)
121,000
0.04%
121,000
0%
08/02/2018
Morgan Stanley Securities Ltd. (Market-Maker)
119,000
0.04%
0
0.16%
08/02/2018
Northern Trust Global Investments Ltd.
113,000
0.03%
0
0%
08/02/2018
Goldman Sachs (US) (Market-Maker)
94,532
0.03%
-78,706
0.15%
11/18/2016
Hargreaves Lansdown Asset Management Ltd.
72,000
0.02%
5,000
0.01%
08/02/2018
UBS Asset Management (Americas) Inc.
72,000
0.02%
1,000
0%
08/02/2018
| Address |
Sovereign House
Cambridge Cambridgeshire CB24 9BZ
United Kingdom
|
|
Employees
|
- |
| Website |
http://gwpharm.co.uk |
| Updated |
07/08/2019 |
| GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. It operates through the following segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. |
